Glutathione deficiency as a prognosis for survival in aids
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsLeonore A. Herzenberg, Stephen C. DeRosa, Leonard A. Herzenberg, Mario Roederer
Life of this patent
Estimating the term…
Abstract
Glutathione levels are determined using a glutathione surrogate in HIV-positive patients to evaluate survival longevity and determine appropriate treatment. Low glutathione levels indicate a need for a glutathione enhancing supplement and a more aggressive therapeutic regimen, as well as diminishing drugs which may result in the reduction of available glutathione.
Claims7
A method for evaluating the probability of an HIV positive patient surviving over two to three years following the evaluation, said method comprising:
- determining the glutathione level, directly or indirectly, in the blood cells of said patient or a fraction thereof,
- wherein a reduced glutathione level as compared to an average level in HIV negative humans is indicative of a reduced probability of survival in comparison to HIV negative humans.
A method for evaluating the probability of survival of an HIV positive patient over two to three years following the evaluation, said method comprising:
- contacting cells from whole blood with a glutathione derivatizing agent to produce a fluorescent conjugate;
- determining the amount of said fluorescent conjugate as indicative of the glutathione level in the blood cells of said patient or a fraction thereof by measuring the fluorescence of said sample;
- wherein a reduced glutathione level as compared to an average level in HIV negative humans is indicative of a reduced probability of survival in comparison to HIV negative humans.
Dependencies are inferred from the claim text.